

7 July 2021

Title: Modulating proinflammatory processes using tocilizumab in major depressive disorder

EudraCT number: 2017-004624-30


Sponsor code: TOC17_01

Re: premature termination of study

Dear Colleagues:

This is to inform you of the early termination of our study titled, “Modulating proinflammatory processes using tocilizumab in major depressive disorder.”

While we saw some success in enrolling participants to our study (seven participants were enrolled between September 2018 and November 2019), this proved burdensome and expensive to an extent that we unblinded the study to determine if early signs of an experimental effect could be detected. As can be seen in the graph below, participants receiving treatment (tocilizumab) and placebo did not differentiate during or just after a one-month course of treatment with respect to change from baseline in depressive symptoms as measured by the Montgomery-Åsberg Depression Rating Scale.



Sincerely (on behalf of the CSAN Experimental Medicine Team),

J. Paul Hamilton, Ph.D.

Associate Professor / Universitetslektor

Center for Social and Affective Neuroscience

Center for Medical Image Science and Visualization

Department of Biomedical and Clinical Sciences

Linköping University